Compare BOH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOH | LQDA |
|---|---|---|
| Founded | 1897 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2018 |
| Metric | BOH | LQDA |
|---|---|---|
| Price | $67.90 | $31.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $72.00 | $37.40 |
| AVG Volume (30 Days) | 346.7K | ★ 1.1M |
| Earning Date | 01-26-2026 | 11-03-2025 |
| Dividend Yield | ★ 4.09% | N/A |
| EPS Growth | ★ 22.78 | N/A |
| EPS | ★ 4.09 | N/A |
| Revenue | ★ $677,459,000.00 | $69,216,000.00 |
| Revenue This Year | $15.10 | $994.17 |
| Revenue Next Year | $8.26 | $169.25 |
| P/E Ratio | $16.71 | ★ N/A |
| Revenue Growth | 8.56 | ★ 343.41 |
| 52 Week Low | $57.45 | $11.26 |
| 52 Week High | $76.00 | $36.41 |
| Indicator | BOH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 42.54 |
| Support Level | $70.28 | $33.45 |
| Resistance Level | $70.34 | $35.20 |
| Average True Range (ATR) | 1.09 | 1.54 |
| MACD | -0.37 | -0.53 |
| Stochastic Oscillator | 22.25 | 2.83 |
Bank of Hawaii Corp provides a broad range of financial products and services predominantly to customers in Hawaii, Guam, and other Pacific Islands. The Bank's subsidiaries are engaged in equipment leasing, securities brokerage, investment advisory services, and providing credit insurance. It is organized into three business segments for management reporting purposes: Consumer Banking, Commercial Banking, and Treasury and Other. Majority of the revenue is generated from Consumer Banking segment which offers a broad range of financial products and services, including loan, deposit and insurance products; private banking and international client banking services; trust services; investment management; and institutional investment advisory services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.